Melbourne's ophthalmology community — anchored by the Royal Victorian Eye and Ear Hospital and the Centre for Eye Research Australia at the University of Melbourne — manages one of Australia's largest glaucoma patient populations. Lumigan (Bimatoprost 0.01%) provides Melbourne glaucoma patients with the same proven intraocular pressure reduction as brand Lumigan at significantly reduced cost, supporting the lifelong adherence essential to preventing glaucomatous vision loss.
Glaucoma affects approximately 300,000 Australians with many undiagnosed, and Melbourne's ageing population creates growing demand for affordable, sustainable glaucoma therapy. The cost of lifelong eye drops is a genuine adherence barrier for many Melbourne patients — affordable Lumigan supply from Unnati Pharmax directly supports the consistent daily use that protects long-term vision.
Visit medshopy.com or WhatsApp +91 82650 41513 for Melbourne supply.
Glaucoma affects approximately 300,000 Australians with many undiagnosed, and Melbourne's ageing population creates growing demand for affordable, sustainable glaucoma therapy. The cost of lifelong eye drops is a genuine adherence barrier for many Melbourne patients — affordable Lumigan supply from Unnati Pharmax directly supports the consistent daily use that protects long-term vision.
Visit medshopy.com or WhatsApp +91 82650 41513 for Melbourne supply.
❓ How does Bimatoprost in Lumigan lower eye pressure in glaucoma — what is its mechanism?
Intraocular pressure (IOP) is determined by the balance between aqueous humour production by the ciliary body and its drainage through two pathways: the trabecular meshwork (the primary drainage channel) and the uveoscleral pathway (an alternative route). Bimatoprost is a prostamide — structurally related to prostaglandins — that primarily increases aqueous humour outflow through the uveoscleral pathway by relaxing the ciliary muscle and widening the spaces through which fluid can drain. Unlike older glaucoma drops that reduce aqueous production (beta-blockers like Timolol) or some that work mainly through the trabecular route, Bimatoprost's uveoscleral mechanism provides robust, once-daily IOP reduction of 25-35% — among the most effective single-agent reductions available. Melbourne's ophthalmologists favour it as first-line monotherapy for many newly diagnosed open-angle glaucoma patients for this reason.
